Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Efpeglenatide, a new GLP-1 receptor agonist, referenced to liraglutide in Phase II trial.
Read More »EXCEED Trial: Efpeglenatide Displays Significant Reduction in HbA1c and Body Weight
Preventing Diabetes with Resistance Training or Aerobic Exercise
Can resistance training improve beta-cell function in patients with prediabetes?
Read More »Medications That Can Reduce The Conversion To Type 2 Diabetes
Pharmacological interventions may have a role to play in preventing progression to type 2 diabetes, but are they more important than lifestyle factors?
Read More »Sugar Substitutes and Type 2 Diabetes
A new study looks at the growing use of non-nutritive sweeteners and if they may cause, or help prevent, type 2 diabetes.
Read More »An Overview of Double Diabetes (DD)
What do we know today about patients who have double diabetes?
Read More »Depression + Diabetes = Increased Risk for Cardiovascular Outcomes
Patients who have diabetes should be screened for psychological risk factors.
Read More »Nutritional Approach in Management of Diabetes or Prediabetes
How effective is medical nutrition therapy in improving diabetes and prediabetes outcomes?
Read More »Who, and When, Should We Screen for Metabolic Risk?
Updated guidelines on how best to screen for metabolic risk to help with the prevention of both type 2 diabetes and ASCVD.
Read More »Decreased eGFR and Increased Albuminuria Highly Predictive of Major Clinical Outcomes in T2DM Patients
Combined analysis of eGFR and albuminuria over 2 years has been shown to predict T2DM patients’ risk for major macrovascular outcomes.
Read More »Oral Semaglutide – A Phase 3 Trial in Patients with Type 2 Diabetes
Final results from a phase 3 study preceded FDA approval of oral semaglutide.
Read More »